IMUX logo

IMMUNIC INC

IMUXNASDAQ
πŸ† #3932 by market capEarnings Nov 11 Β· PreUS Equity
$7.81β–Ό $0.16 (βˆ’2.01%)
After hours Β· at close
πŸ””
Track IMUX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.0%
7dβ–² 8.6%
14dβ–² 10.5%
30dβ–Ό 12.6%
ytdβ–² 46.5%
1yβ–Ό 1.8%
🏦Market Cap
$107M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$7.60 – $8.12
52-Week Range
$5.06 – $17.43
Volume (shares)
15,543
Avg Volume (shares)
β€”
Shares Outstanding
13.6M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-1.6
P/S Ratio
0.0x
EPS (TTM)
$-2.62
Dividend Yield
0.00%
Dilution (1yr)
+33.5%
IMUX logo

IMMUNIC INC

IMUX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$103Mβ–² +5.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$86Mβ–² +1.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.0Mβ–² +33.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15Mβ–Ό βˆ’$20M YoY
StockOtter Β· stockotter.space

About IMMUNIC INC

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORΞ³t, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
18 analysts
Strong Buy9
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.